Payment overview · 2025
General Payments
$585.15
30 reported records · 9 companies
Healthcare provider profile · identity verified
Kevin Davis, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · HINDMAN, KY · NPI 1811903529
Verified facts
What the public records show
CMS Open Payments records show Kevin Davis, PA received $585.15 in general payments during 2025 across 30 reported records.
ABBVIE INC. accounted for 27.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $162.81 | 27.8% | 8 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $149.11 | 25.5% | 8 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $85.42 | 14.6% | 4 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $61.49 | 10.5% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $42.47 | 7.3% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $26.52 | 4.5% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $21.84 | 3.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.12 | 3.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.37 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $585.15 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $149.12 | 7 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $149.11 | 8 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $149.11 | 8 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $85.42 | 4 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $61.49 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.22 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $26.52 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $21.84 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $21.84 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.12 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.69 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 309 | 94 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 240 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 208 | 59 |
| Metformin Hcl | Metformin Hcl | 207 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 174 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 171 | 58 |
| Omeprazole | Omeprazole | 170 | 44 |
| Tizanidine Hcl | Tizanidine Hcl | 137 | 48 |
| Gabapentin | Gabapentin | 131 | 29 |
| Atorvastatin Calcium | Atorvastatin Calcium | 126 | 41 |
| Farxiga | Dapagliflozin Propanediol | 112 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 106 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 97 | 37 |
| Testosterone Cypionate | Testosterone Cypionate | 92 | 23 |
| Potassium Chloride | Potassium Chloride | 86 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 85 | 35 |
| Losartan Potassium | Losartan Potassium | 85 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 35 |
| Ozempic | Semaglutide | 79 | 12 |
| Simvastatin | Simvastatin | 76 | 24 |
| Cefdinir | Cefdinir | 71 | 55 |
| Ondansetron Odt | Ondansetron | 70 | 28 |
| Trazodone Hcl | Trazodone Hcl | 69 | 17 |
| Levofloxacin | Levofloxacin | 68 | 40 |
| Tramadol Hcl | Tramadol Hcl | 68 | 14 |
| Allopurinol | Allopurinol | 67 | 28 |
| Amoxicillin | Amoxicillin | 67 | 44 |
| Buspirone Hcl | Buspirone Hcl | 66 | 21 |
| Furosemide | Furosemide | 65 | 28 |
| Meloxicam | Meloxicam | 65 | 23 |
| Sertraline Hcl | Sertraline Hcl | 65 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 21 |
| Famotidine | Famotidine | 63 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 61 | 26 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 60 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 59 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 59 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | 18 |
| Carvedilol | Carvedilol | 57 | 20 |
| Mounjaro | Tirzepatide | 57 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 20 |
| Azithromycin | Azithromycin | 49 | 35 |
| Spironolactone | Spironolactone | 49 | 15 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 48 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 48 | 16 |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 48 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 48 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 12 |
| Prednisone | Prednisone | 46 | 31 |
| Ibuprofen | Ibuprofen | 45 | 18 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 44 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 32 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 41 | 41 |
| Nifedipine Er | Nifedipine | 39 | 13 |
| Fenofibrate | Fenofibrate | 37 | suppressed |
| Mupirocin | Mupirocin | 36 | 22 |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 14 |
| Atenolol | Atenolol | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 17 |
| Baclofen | Baclofen | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Nystatin | Nystatin | 27 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 12 |
| Cephalexin | Cephalexin | 25 | 20 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 25 | 20 |
| Lactulose | Lactulose | 25 | 15 |
| Montelukast Sodium | Montelukast Sodium | 25 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 19 |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Eliquis | Apixaban | 18 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Invokana | Canagliflozin | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Humira Pen | Adalimumab | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Enbrel Sureclick | Etanercept | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $585.15 · 30 records | ABBVIE INC. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, AREXVY, ARISTADA, BEXSERO, CAPLYTA, Dexcom G6 Transmitter, FANAPT, FREESTYLE LIBRE 3, HETLIOZ, LYBALVI, Prolastin-C Liquid, QULIPTA, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error